AWS Health Innovation Podcast

In this engaging discussion, Adam Laing, Co-founder and Chief Scientific Officer of IMU Biosciences, shares how his company uses AI to decode the immune system. He explains the innovative technology behind measuring 80 million data points from blood samples, enabling personalized insights into health. The conversation highlights the potential of predictive immune profiling in tailoring treatments for diseases like cancer and autoimmune disorders. Laing also emphasizes the power of collaboration among multidisciplinary teams to drive breakthroughs in precision medicine.

Gabriel Jones, CEO and co-founder of Proprio, shares his expertise on how AI, computer vision, and augmented reality are revolutionizing surgery. He discusses Proprio's innovative approach to surgical precision through real-time 3D visualization and predictive analytics. With a diverse background in neurosurgery and engineering, Jones emphasizes the importance of interdisciplinary collaboration in driving innovation. The conversation also touches on the iterative product development process and the future of equitable healthcare access enhanced by advanced technologies.

In this episode of the AWS Health Innovation Podcast, host Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, sits down with Lindsay Edwards, CTO and President of Platform at Relation, a biotech company leveraging single-cell multi-omics, machine learning, and clinical insights to develop transformational medicines. 1. What is Relation's unconventional approach to drug discovery? Lindsay Edwards, a former musician turned drug hunter, embodies Relation's bold mission to transform drug discovery through multidisciplinary expertise bridging biology, data science, and creative intuition. Relation harnesses human genetic insights and single-cell data to pinpoint superior drug targets, addressing a critical bottleneck in pharmaceutical R&D. 2. How does Relation integrate lab experiments and machine learning? Relation's "Lab-in-the-Loop" approach tightly integrates wet lab experiments with machine learning, iteratively refining models that map genetic variation to disease mechanisms. Interdisciplinary collaboration between biologists, data scientists, and computational experts catalyzes this symbiosis of lab and AI. 3. How does Relation's initial focus in developing precision medicines for osteoporosis open opportunities in other therapuetic areas? By studying osteoblasts and genetic determinants of bone density, Relation aims to develop anabolic therapies driving new bone growth, addressing the large unmet need in osteoporosis with precision medicine. Their traction in osteoporosis shows how Relation can apply biological signals to improve machine learning modeling, uncover novel therapeutic targets. To learn more about Relation and their transformative approach to drug discovery, visit their website: https://www.relationrx.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, sits down with Mostafa ElSayed, Co-founder and CEO of Automata, a company revolutionizing the way scientists work in labs by providing a full-stack solution for lab automation. How does Automata's LINQ platform streamline drug discovery workflows? Automata's LINQ platform integrates robotics, instruments, and cloud software, addressing inefficiencies in life sciences labs. As a modular "work cell", it captures structured data to accelerate collaboration and time-to-market for therapeutics. What inspired Mostafa ElSayed's vision for Automata? Mostafa ElSayed's background in architecture sparked an interest in robotics, leading him to co-found Automata and pioneer a full-stack lab automation solution. His vision fuses design principles with cutting-edge technology to transform drug R&D. What does ElSayed envision for the future of drug discovery? ElSayed envisions AI-driven drug discovery becoming the norm within a decade, with a shift towards computational "in silico" approaches over lab-based "in vitro" methods. Robust data and transparency will increase confidence in clinical candidates. How does Automata balance product vision with user feedback? Automata balances product vision with user feedback, investing heavily in hardware modularity, software UX/UI, and developer experience. Design drives customer success by optimizing different user journeys through an experience lens. To learn more about Automata and their innovative lab automation solutions, visit https://automata.tech/. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Rajarshi Banerjee, CEO of Perspectum, transforms chronic disease management with AI-powered medical imaging. His journey began with non-invasive techniques during his PhD at Oxford, leading to innovations like LiverMultiScan. The discussion reveals how virtual biopsies replace traditional invasive methods, driving advancements in personalized medicine. Banerjee highlights the importance of equitable healthcare solutions, addressing conditions such as long COVID and diabetes. The conversation also touches on the role of empathy in integrating AI into diagnostics.

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, interviews Dr. Harvey Karp, Founder and CEO of Happiest Baby, the company behind the SNOO Smart Sleeper - a robotic bassinet designed to calm fussing infants and establish healthy sleep patterns. How did Dr. Karp's experience as a pediatrician lead to the creation of the SNOO? As a pediatrician and child development expert, Dr. Karp witnessed firsthand the challenges parents face with excessive infant crying and sleep deprivation. His quest to soothe colic and promote healthy sleep led him to develop the SNOO, a smart bassinet that mimics the womb environment by responding to fussing with gentle rocking and soothing sounds. What makes the SNOO a groundbreaking product in the healthcare industry? In a pioneering move, the SNOO bassinet received FDA de novo approval in March 2023 as a medical device, making it the first smart crib to achieve this status. This clearance paves the way for insurance coverage and rental programs, aligning with Karp's vision of making this technology accessible to families through employer benefits and other initiatives. What challenges did Dr. Karp face in bringing the SNOO to market? Transforming the SNOO concept into a viable product took over two years of engineering challenges to create a smooth, quiet rocking motion. Despite funding obstacles, Karp leveraged his existing brand and persevered, demonstrating the entrepreneurial perseverance required to bring innovative healthcare solutions to market. How does the SNOO challenge traditional beliefs about infant care? The SNOO raises intriguing questions about optimal infant care practices. While conventional wisdom suggests leaving babies alone is best for brain development, Karp theorizes that rocking and shushing may be neurological needs beyond just soothing techniques, challenging traditional beliefs about infant care. How has the SNOO been received by customers and healthcare professionals? With a remarkable net promoter score of 89 and use in 160 hospitals, the SNOO demonstrates extremely high customer satisfaction by reducing nurse workloads. Karp's focus on solving real family pain points is driving strong product-market fit, as evidenced by the positive reception from both parents and healthcare professionals. To learn more about Happiest Baby and the SNOO Smart Sleeper, visit http://www.happiestbaby.com/. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at Amazon Web Services, sits down with Raviv Pryluk, CEO and Co-Founder of PhaseV, a company leveraging cutting-edge technologies like reinforcement learning and causal machine learning to revolutionize clinical trial design and execution. 1. How did Raviv and his co-founder identify the clinical trials space as ripe for innovation? Raviv shares the extensive research and criteria-driven process he undertook with co-founder Elad to identify the clinical trials space as ripe for innovation. They sought an area with major positive impact potential that leveraged their expertise in machine learning, neuroscience, and engineering. 2. What innovative technologies does PhaseV employ to transform clinical trials? PhaseV's platforms harness cutting-edge technologies like reinforcement learning and causal ML to enable adaptive trial designs and advanced data analysis. This allows more efficient, ethical trials with faster detection of subgroups responding differently to treatments. 3. How does PhaseV's causal ML platform extract insights from complex biological data? PhaseV's causal ML platform can analyze intricate biological mechanisms and multi-endpoint trials to identify true causal relationships, not just correlations. This surfaces actionable insights into why certain patient subgroups respond better to specific drugs. 4. How does PhaseV aim to accelerate drug development timelines? By leveraging machine learning for surrogate endpoints and virtual head-to-head comparisons in Phase 2, PhaseV aims to predict trial outcomes faster. This could dramatically reduce the 10+ year, $3B+ timeline for new drug approvals. 5. How is PhaseV positioned to capitalize on regulatory shifts post-COVID? The pandemic prompted increasing regulatory flexibility and digitization in clinical trials. PhaseV is well-positioned to capitalize on this evolving landscape and usher in a new era of precision medicine through innovative trial methodologies. 6. How does PhaseV build its multidisciplinary team? Raviv discusses PhaseV's strategic hiring approach, carefully assembling a diverse team spanning software, data science, medicine, and biology. Maintaining an "adaptive" mindset allows continuous reevaluation based on new data. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Medication-related problems are a massive burden on healthcare systems, leading to adverse events, suboptimal treatments, and skyrocketing costs. MDI Health has developed an AI-driven pharmacology platform that autonomously optimizes personal medication regimens by analyzing thousands of pharmacological and patient parameters. Joining us today is Avishai Ben-Tovim, CEO and Co-Founder of MDI Health, to share how their powerful AI identifies high-risk patients, provides clinicians with evidence-based recommendations to reduce risks in real-time, and helps payers and providers execute those recommendations - ultimately reducing total care costs while improving quality.What is MDI Health's approach to Medication Therapy Mastery? MDI Health's AI platform analyzes thousands of pharmacological and patient parameters to optimize medication regimens across populations. It identifies high-risk patients for adverse drug events and provides real-time recommendations to reduce risks and lower care costs.How did MDI Health overcome barriers in the healthcare industry? Avishai discusses how MDI Health conducted clinical studies, secured early customers through resourcefulness, and provided clinical validation to convince chief medical officers of their value proposition.What is the concept of a Collaborative AI Co-Pilot? MDI Health's evidence-based algorithm maps pharmacological rules, trained by comparing to expert analysis on real cases. It complements existing systems by surfacing insights and suggested actions clinicians often miss.How does MDI Health aim to align healthcare incentives? Avishai aims to enable data exchange and aligned incentives between health plans and providers. MDI Health's solution improves efficiency and holistic patient care impact for all stakeholders.What is MDI Health's approach to building a mission-driven culture? From the start, MDI Health prioritized building a strong organizational culture focused on the mission. They foster ownership, openness, learning, and retaining employees who deeply care.How does MDI Health educate the market on their solution? MDI Health leverages conferences, relationships, and continuous improvement to educate the market on their proven AI technology and value proposition for medication optimization.Learn more about MDI Health here to understand how their AI-driven pharmacology platform can optimize medication regimens and reduce healthcare costs.Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Accelerating medical decision-making with AI is the mission of Ikerian, a Swiss software company enabling healthcare teams to harmonize and analyze data at scale. In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare and Life Science Startups at AWS, is joined by Carlos Ciller, CEO and co-founder of Ikerian, to discuss their innovative platform and approach. Carlos shares insights into Ikerian's journey, from its origins as a retinal imaging AI startup called RetinAI, to evolving into a comprehensive data platform serving pharmaceutical companies, physicians, and researchers across therapeutic areas. The discussion explores how Ikerian is empowering stakeholders to detect diseases sooner through biomarker identification, optimize treatment decisions with curated insights, expedite clinical collaboration through efficient workflows, and accelerate drug development by aggregating learnings. Carlos also discusses the key components of their scalable cloud platform, their focus on user experience and education, and the entrepreneurial resilience required to bring such an ambitious vision to reality. Founder's Entrepreneurial Journey Carlos Ciller shares his background, from studying in Barcelona to co-founding Icarian in Switzerland. He discusses the resilience and commitment required as an entrepreneur, learning from failures, and the importance of time management after becoming a father. Oculomics: Unlocking Systemic Health The eye provides a window into systemic diseases, a field known as "oculomics." Retinal scanning offers a low-cost, automated diagnostic modality compared to alternatives like MRI, enabling early disease detection and optimized treatment decisions. Diverse Customer Needs, Unified Solution Ikerian caters to pharmaceutical companies (AI, medical, market access teams) and physicians, offering AI analysis, clinical studies, patient identification, decision support, and patient engagement through a unified, cloud-based platform. Scalable Cloud Infrastructure Enabler Leveraging Amazon's scalable cloud infrastructure, Icarian's platform can dynamically scale based on customer needs, comprising image/data management, task processing, clinical viewer, and modular AI components. User-Centric Design for Adoption Recognizing the importance of user experience and education in healthcare, Icarian focuses on user-centric design to drive platform adoption among pharmaceutical companies and physicians. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. To learn more about Ikerian and their innovative platform, visit ikerian.com.

Explore how Ibex AI is revolutionizing cancer diagnosis with artificial intelligence! Discover the founders' journey, fueled by a vision for tech-driven healthcare despite their lack of medical background. Learn about a significant milestone when their AI caught a misdiagnosis at Maccabi Healthcare. The podcast emphasizes the importance of integrating AI into clinical workflows and how these advancements in technology can enhance patient care. Dive into building a purpose-driven team and the critical role of early cancer detection in improving healthcare outcomes.